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OBJECTIVES This study was performed to compare the long-term clinical efficacy of treatment with
metoprolol versus carvedilol in patients with chronic heart failure.
BACKGROUND Beta-adrenergic blockade is of proven value in chronic heart failure. Metoprolol, a selective
beta-blocker, is widely used, but recent trials suggest carvedilol, a nonselective beta-blocker
with alpha-1-receptor antagonist activity and antioxidant activities, is also effective. It is
uncertain, however, if these additional properties of carvedilol provide further clinical benefit
compared with metoprolol.
METHODS In this randomized double-blind control trial, 51 patients with chronic heart failure and mean
left ventricular (LV) ejection fraction of 26% 6 1.8% were randomly assigned treatment with
metoprolol 50 mg twice daily or carvedilol 25 mg twice daily in addition to standard therapy
after a four-week dose titration period for a total of 12 weeks. Response was assessed by a
quality of life questionnaire, New York Heart Association class, exercise capacity (6-min walk
test), radionucleotide ventriculography for LV ejection fraction, two-dimensional echocardi-
ography measurement of LV dimensions and diastolic filling and 24-h electrocardiograph
monitoring to assess heart rate variability.
RESULTS Both carvedilol and metoprolol produced highly significant improvement in symptoms (p ,
0.001), exercise capacity (p , 0.05) and LV ejection fraction (p , 0.001), and there were no
significant differences between the two drugs. Carvedilol had a significantly greater effect on
sitting and standing blood pressure, LV end-diastolic dimension and normalized the mitral
E wave deceleration time.
CONCLUSIONS Both metoprolol and carvedilol were equally effective in improving symptoms, quality of life,
exercise capacity and LV ejection fraction, although carvedilol lowers blood pressure more
than metoprolol. (J Am Coll Cardiol 1999;34:1522–8) © 1999 by the American College of
Cardiology
There is increasing evidence that beta-adrenergic blockade
is useful for patients with chronic heart failure. Several
meta-analyses have provided evidence supporting favorable
effects of b-blockade on left ventricular (LV) ejection
fraction and the combined risk of death and hospitalization
for heart failure (1,2). Metoprolol was the main beta-
blocker studied in the original trials (3–6), but a variety of
selective and nonselective beta-blockers have been used
subsequently (1,2). There are, to date, little data on the
relative advantages or disadvantages of different beta-
blockers in the treatment of chronic heart failure, although
we have previously compared metoprolol with the vasodi-
lating beta-blocker celiprolol (7). Carvedilol is an interesting
drug in that it provides nonselective beta-adrenergic recep-
tor antagonism (beta-1 and beta-2) but in addition has a
alpha-1 adrenergic blocking action and a documented anti-
oxidant activity (8–12). These additional actions of carve-
dilol may provide further clinical benefit for the patient.
Therefore, we have carried out a randomized double-blind
trial to compare carvedilol with metoprolol over a three-
month period to determine their relative effectiveness on
symptoms, exercise capacity, LV systolic and diastolic func-
tion and heart rate variability indices.
METHODS
Trial design. This was a randomized double-blind parallel
group-controlled trial. Patients with typical symptoms of
heart failure and reduced LV ejection fraction (,0.45) were
recruited into the study. After baseline measurements,
patients were randomized to receive treatment either with
metoprolol or carvedilol. Both medications were in identical
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capsules. There was a four-week dose titration period
increasing the dose of carvedilol from 3.125 to 25 mg twice
daily and metoprolol from 6.25 to 50 mg twice daily. Doses
were increased at weekly intervals. Maintenance of doses
was continued for eight weeks (total of 12 weeks of
treatment). At the end of 12 weeks, baseline measurements
were repeated. Clinical assessment was carried out at 1, 2, 4
and 8 weeks. Compliance was checked by counting the
remaining capsules at each visit.
Study objectives. To compare the efficacy and tolerability
of metoprolol and carvedilol by assessment of symptoms
(using the Minnesota Quality of Life Heart Failure Ques-
tionnaire), exercise capacity (6-min walking test), LV ejec-
tion fraction (measured by radionucleotide ventriculography
and echocardiography), LV diastolic function (by Doppler
echocardiography) and heart rate variability by 24-h ambu-
latory electrocardiograph (ECG) monitoring. The primary
end points were symptom score, exercise time and LV
ejection fraction. The study had a 90% power to detect a
55% reduction in symptom score, a 20% increase in the
6-min walking time and a 12% increase in LV ejection
fraction from baseline for each drug group, all of which
would be considered clinically significant.
Study patients. Patients with a clinical diagnosis of
chronic heart failure who were on standard therapy with
diuretics, digoxin and angiotensin-converting enzyme in-
hibitors and with a LV ejection fraction of ,0.45 (by
radionucleotide ventriculography) were recruited. Patients
were excluded if they had significant valvular heart disease as
the etiology of LV dysfunction, active myocarditis, unstable
angina, a documented history of sustained ventricular tachy-
cardia or symptomatic nonsustained ventricular tachycardia
or second- or third-degree atrioventricular block. Patients
with chronic obstructive lung diseases, asthma, long-term
alcohol or drug abuse or chronic renal failure (serum
creatine .200 mmol/liter), hepatic hematological, neuro-
logical or collagen vascular disease were excluded. All
subjects gave written informed consent, and the study was
approved by the Ethics Committee of the Faculty of
Medicine, the Chinese University of Hong Kong.
Study measurements. Baseline measurements included as-
sessment of symptoms using the Minnesota Heart Failure
Symptom Questionnaire, New York Heart Association
(NYHA) class and routine clinical examination (pulse, heart
rate, sitting and standing blood pressure, examination of
jugular venous pressure, position of the apex beat and
presence or absence of a heart murmur or lung rales). A
6-min corridor walk test was carried out. Two baseline walk
tests were carried out and the results averaged. Routine
two-dimensional Doppler echocardiography was performed
with measurement of LV dimensions. Pulse-wave Doppler
echocardiography was performed to assess mitral inflow
velocities. The usual variables were measured: peak early
mitral filling velocity (E wave), peak atrial filling velocity (A
wave), ratio of the peak early and atrial filling velocities
(E/A), deceleration time of the E wave (DT) and isovolu-
mic relaxation time (IVRT), as previously described (13).
Radionucleotide ventriculography was used to assess LV
ejection fraction in the usual way. A 24-h ambulatory ECG
monitoring was performed at baseline and at 12 weeks.
Analysis was undertaken using the Marquette (Milwaukee,
Wisconsin) MARS 8000 analyzer. Standard measurements
of heart rate variability by spectral and time domain analyses
were undertaken (14). Routine blood laboratory tests were
performed at baseline, and at four and eight weeks.
Statistical analysis. Differences between the treatment
groups were carried out by repeated-measures analysis of
variance for continuous variables (ANOVA) with Bartlets
test with homogeneity variances and Tukey-Kramer multi-
ple comparison test if p , 0.05, Friedman’s test for non-
parametric data and Fisher exact test for differences between
proportions. Differences between baseline and week 12
within groups were tested by paired t tests, and Wilcoxon
matched pairs signed ranks test for nonparametric data. The
results are expressed as mean 6 SEM. Differences were
considered significant if p , 0.05.
RESULTS
Subjects. Fifty-one patients with a mean LV ejection
fraction of 26 6 1.8% were recruited in the study, 26 re-
ceiving metoprolol and 25 receiving carvedilol. There were
no significant differences in age, gender or other baseline
characteristics (Table 1). The majority had idiopathic di-
lated cardiomyopathy (45%) with ischemic cardiomyopathy
on the etiology in 22% and hypertensive heart disease in
33%. All but one patient were taking an angiotensin-
converting enzyme inhibitor or angiotensin II receptor
antagonist. The average daily dose of frusemide was similar
in both groups. There were no significant differences be-
tween the two groups at baseline.
Withdrawals. In the carvedilol group, five patients did not
complete the study. Four patients were withdrawn because
of worsening symptoms, in particular, weakness and dizzi-
ness. One patient was withdrawn because of the develop-
ment of angioneurotic edema. In the metoprolol group,
three patients were withdrawn, one because of increased
breathlessness, who subsequently died. There were no
differences between carvedilol and metoprolol (p 5 0.46,
Fisher exact test).
Symptoms. The results of the symptom (quality of life)
questionnaire score and assessment of NYHA functional
class are shown in Table 2. Both drugs were associated with
Abbreviations and Acronyms
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a highly significant reduction in symptom questionnaire
score and NYHA class. However, there were no significant
differences between metoprolol and carvedilol.
Blood pressure and heart rate (Table 2). At 12 weeks,
carvedilol produced a highly significant (p , 0.001) reduc-
tion in sitting and standing systolic and diastolic blood
pressures compared with baseline. Metoprolol had no sig-
nificant effect on sitting systolic or diastolic blood pressure
or standing systolic blood pressure but had a mild effect on
standing diastolic blood pressure. The differing effects on
diastolic blood pressure between the two drugs were signif-
icant (p 5 0.01). Both drugs had a highly significant effect
on heart rate reducing the mean resting heart rate from
85 6 2.52 to 64 6 2 beats/min for metoprolol and 83 6 2.7
to 65 6 2.2 beats/min for carvedilol (both p , 0.001).
Exercise capacity (Table 2). Both drugs were associated
with a significant improvement in exercise capacity as
measured by the 6-min walk test. This effect appeared to be
slightly greater with metoprolol than carvedilol, but the
differences between the two drugs were not significant.
LV systolic function (Table 3). Both drugs produced a
highly significant increase in LV ejection fraction (meto-
prolol 7 6 1.9% and carvedilol 8 6 2.1%), but there was no
significant difference between the drugs. Carvedilol, but not
metoprolol, reduced LV end-diastolic dimension signifi-
cantly.
LV diastolic function (Table 3). Neither drug produced a
significant change of peak mitral E wave velocity. Both
carvedilol and metoprolol prolonged the deceleration time
of the mitral E value towards normal, but this reached
statistical significance only in the carvedilol group (p ,
0.001) in whom the deceleration time was normalized.
There was also a reduction in the E/A ratio, which was
significant for both metoprolol and carvedilol.
Heart rate variability indices (Table 4). Apart from the
predictable changes on average, minimum and maximum
heart rate and NN, there were no significant changes in any
of the time domain or spectral heart rate variability indices
between baseline and week 12 for either metoprolol or
carvedilol.
Table 1. Baseline Clinical Characteristics of Study Patients
Metoprolol
(n 5 26)
Carvedilol Group
(n 5 25) p Value
Age (years) 60.4 (2.3) 58.7 (3.0) 0.65
Range 35–80 33–86
Gender
Male 23 17
Female 3 8
Etiology
IDC 10 13
ICM 5 6
HTHD 11 6
NYHA functional class
II 7 10
III 19 14
IV 0 1
Mean NYHA class 2.7 (0.09) 2.6 (0.11) 0.53
Symptom questionnaire score 13.1 (1.8) 17.2 (3.0) 0.23
ETT (6-min walk, feet) 1164 (46) 1122 (51) 0.55
Baseline blood pressure (mm Hg)
Sitting 126(3)/75(3) 130(5)/78(3) 0.51/0.51
Standing 127(3)/78(3) 130(5)/83(3) 0.54/0.28
Heart rate (beats/min) 84.8 (2.5) 82.8 (2.7) 0.60
LVEF (%) 25.5 (1.8) 26.4 (1.8) 0.72
LVEDD (cm) 6.8 (0.2) 6.7 (0.2) 0.93
FS (%) 13.8 (1.0) 13.7 (0.7) 0.88
Treatment
Frusemide 24 24
Frusemide mean dose (mg) 49 (7.0) 58 (8)
ACEI/AIIRA 25 24
Nitrates 16 16
Values are mean 6 SEM.
ACEI 5 angiotensin-converting enzyme inhibitor; AIIRA 5 angiotensin II receptor antagonist; ETT 5 exercise tolerance
test; FS 5 LV fractional shortening; HD 5 heart disease; HTHD 5 hypertensive heart disease; ICM 5 ischemic
cardiomyopathy; IDC 5 idiopathic dilated cardiomyopathy; LVedd 5 LV end diastolic dimension; LVEF 5 LV ejection
fraction (gated blood pool scan).
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DISCUSSION
In this three-month study comparing metoprolol and carve-
dilol in patients with chronic heart failure, we have dem-
onstrated that both agents significantly improved symptoms
(as judged by a Quality of Life Questionnaire and NYHA
class), exercise capacity and LV ejection fraction. Carvedilol
lowered resting and sitting blood pressure more than meto-
prolol and also reversed the shortening of the deceleration
time of the mitral E wave more than metoprolol. However,
apart from these differences, there were no other apparent
advantages of carvedilol over metoprolol. Both drugs have
been shown previously to improve symptoms and LV
ejection fraction (1–11). However, the effect on exercise
capacity has been variable. Most previous studies with
metoprolol have shown an improvement in exercise capacity
in the long term, but improvement in exercise capacity has
not been a consistent feature in the larger trials of carvedilol
(8). It has been suggested that improvement in exercise
capacity may be greater with selective beta-1 receptor
antagonists because the beta-2-adrenoreceptor-mediated
vasodilatation on exercise is preserved. Although the in-
crease in exercise capacity in our study was slightly greater
with metoprolol, the difference was not significant, and both
drugs significantly increased exercise capacity. Previous
studies have used a variety of methods of assessing exercise
capacity. The robustness of the 6-min walk test is improved
if two baseline measurements are performed, as was done in
this study (15).
Our results differ slightly from those of Gilbert et al. (16).
In that study, the authors suggest that compared with
metoprolol, carvedilol was associated with greater improve-
ment in NYHA functional class, and there was a trend (all
not significant) for carvedilol to produce a relatively greater
improvement in LV ejection fraction, stroke volume and
stroke work. However, that study, unlike ours, was not a
randomized trial comparison of metoprolol against carve-
Table 2. Effects of Metoprolol or Carvedilol on Symptoms, Exercise Capacity, Blood Pressure and Heart Rate (Mean 6 SEM)
Metoprolol at week: Carvedilol at week:
0 4 8 12 0 4 8 12
Symptom questionnaire
score
13.1 (1.8) 9 (1.5) 6.5 (1) 4.8* (1.4) 17.2 (3) 13.1 (2.2) 11.3 (2.5) 8.1* (2)
NYHA functional class
I 0 1 1 1 0 1 0 1
II 7 15 16 19 10 14 14 14
III 19 9 7 3 14 8 6 5
IV 0 0 0 0 1 0 0 0
Mean 2.7 (0.09) 2.3 (0.11) 2.2 (0.1) 2.1* (0.09) 2.6 (0.11) 2.3 (0.11) 2.3 (0.1) 2.2* (0.12)
Blood pressure (mm Hg)
Sitting SBP 126 (3) 117 (3) 121 (4) 117 (4) 130 (5) 122 (5) 121 (7) 116 (6)*
Sitting DBP 75 (3) 72 (2) 70 (2) 72 (2) 78 (3) 70 (4) 72 (3) 68 (3)*
Standing SBP 127 (3) 120 (3) 124 (4) 122 (3) 130 (5) 125 (5) 123 (6) 117 (5)*
Standing DBP 78 (3) 74 (2) 73 (3) 71 (3)‡ 83 (3) 74 (4) 74 (3) 72 (3)*
Heart rate (beat/min) 84.8 (2.5) 65.7 (2.2) 64.1 (3.1) 64.1* (2.0) 82.8 (2.1) 66.6 (2.1) 65.6 (2.2) 65.4* (2.2)
ETT (6-min walk, feet) 1164 (46) 1168 (48) 1162 (51) 1263† (52) 1122 (51) 1098 (49) 1160 (64) 1194‡ (63)
*p , 0.001 †p , 0.01 ‡p , 0.05 week 12 vs. baseline.
DBP 5 diastolic blood pressure; ETT 5 exercise tolerance time; NYHA 5 New York Heart Association; SBP 5 systolic blood pressure.
Table 3. Effect of Metoprolol or Carvedilol Therapy on Systolic and Diastolic LV Function
Metoprolol Carvedilol
Baseline Week 12 Baseline Week 12
LVEF % 25 6 1.8 31 6 2.5* 26 6 1.8 35 6 2.6*
LV FS 13.8 6 1.0 20 6 1.4* 13.6 20.9 6 1.4*
LVedd (cm) 6.7 6 0.17 6.4 6 0.19 6.7 6 0.2 6.1 6 0.3*
Mitral E (cm/s) 0.77 6 0.05 0.68 6 0.04 0.7 6 0.06 0.67 6 0.06
Mitral A (cm/s) 0.58 6 0.05 0.77 6 0.06† 0.6 6 0.07 0.7 6 0.09
E/A ratio 1.6 6 0.2 1.1 6 0.2† 1.5 6 0.2 1.0 6 0.2‡
Mitral DT (ms) 152 6 14 199 6 14 145 6 9.8 214 6 15*
*p , 0.001; †p , 0.01; ‡p , 0.05 week 12 vs. baseline.
LVedd 5 LV end-diastolic dimension; LVEF 5 LV ejection fraction; LVFS 5 LV fractional shortening; mitral A 5 peak
velocity of mitral atrial wave; mitral DT 5 deceleration time of mitral E wave; mitral E 5 peak velocity of mitral early filling
wave.
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dilol but a comparison of two substudies from two different
placebo-controlled trials, allowing for the possibility of
considerable patient heterogeneity and bias.
Effect on blood pressure. The greater effect on blood
pressure by carvedilol is probably due to its alpha-adrenergic
receptor antagonism properties. This effect on blood pres-
sure was still apparent at 12 weeks, indicating that alpha
receptor blockade is still operative after three-month ther-
apy. In previous studies with alpha-blockers in heart failure,
the benefits have not been sustained, due to the develop-
ment of tolerance. Kukin et al. (17) were unable to demon-
strate any benefit of combined therapy with doxazosin and
metoprolol compared with metoprolol alone after three
months of continuous treatment. However, in hypertension,
Weber et al. (18) demonstrated that there was a chronic
difference between carvedilol and metoprolol, and their
results suggest that carvedilol’s vasodilatory action is not
subject to the development of tolerance. Our study would
support this view.
Diastolic function. The reduction in E/A ratio by both
metoprolol and carvedilol suggests that over the long term,
both reduce the early filling pressure gradient across the
mitral valve and hence velocity, that is, the filling pattern is
less restrictive, although the fall in peak E wave velocity
alone was not significant for either drug. The increased A
wave velocity seen particularly with metoprolol suggests
either an increased atrial contribution due to the prolonga-
tion of diastole consequent on the bradycardia, or improved
atrial contractile function. Our result with metoprolol is
similar to those of Andersson et al. (19), who also found
that therapy with metoprolol was associated with a decrease
in E-wave deceleration time, implying a less restrictive
filling pattern. In contrast, Quaife et al. (20) found that
carvedilol did not change various radionucleotide parame-
ters of LV diastolic function, including peak filling rate and
time to peak filling in patients with idiopathic or ischemic
cardiomyopathy. It is difficult to explain the difference
between these and our results. However, it is well known
that the Doppler mitral flow parameters are influenced by
changes in loading conditions (21,22), and the larger
changes we detected with carvedilol are probably due to its
greater effect on afterload and preload. This may explain
carvedilol’s greater effect on the mitral deceleration time,
although the differences were small, and there was also a
trend for improvement with metoprolol. However, these
changes in the mitral diastolic filling patterns may have
clinical relevance in light of previous studies showing that a
short deceleration time (a restrictive filling pattern) is
associated with a worse prognosis (23–25). Furthermore,
Little et al. (26) demonstrated that the deceleration time
predicts LV chamber stiffness. In addition, carvedilol may,
because of its alpha-antagonism, exert a greater effect on the
extracellular matrix and chamber stiffness than metoprolol.
Recent studies have shown that norepinephrine increases
extracellular matrix via alpha-adrenoceptor stimulation in
human vascular smooth muscle (27). The greater effect of
carvedilol on the mitral deceleration time may reflect a
greater effect on diastolic function and possibly, therefore,
on mortality. Our study, of course, is too small to test a
mortality effect of the two drugs, and this is currently being
prospectively evaluated in the Carvedilol or Metoprolol
European Trial (COMET).
Heart rate variability. Neither carvedilol nor metoprolol
significantly improved heart rate variability. In a previous
study, we demonstrated that metoprolol did improve high-
frequency power and baroreceptor function (28). However,
in that study, the measurements were done over short 5- to
7-min recording periods during controlled respiration. In
the UK-Heart Study (29), heart failure patients with
SDNN ,50-ms mortality had a significantly higher mor-
Table 4. Effect of Metoprolol or Carvedilol on Spectral and Time Domain HRV Intervals
Metoprolol Carvedilol
Baseline Week 12 p Value Baseline Week 12 p Value
Total power ln (ms2) 5.9 6 0.20 5.7 6 0.26 0.42 5.9 6 0.18 5.8 6 0.17 0.85
LF power ln (ms2) 4.2 6 0.27 4.2 6 0.30 0.92 4.3 6 0.28 4.4 6 0.22 0.31
HF power ln (ms2) 3.6 6 0.23 3.6 6 0.24 0.89 3.4 6 0.20 3.5 6 0.15 0.43
NN (ms) 696.0 6 21.5 830.09 6 16.81 , 0.001 729.3 6 22.70 820.7 6 20.03 , 0.001
SDNN (ms) 79.7 6 3.93 86.2 6 5.50 0.20 82.9 6 5.80 75.3 6 4.50 0.16
SDANN (ms) 70.7 6 4.70 74.9 6 5.62 0.48 73.7 6 5.31 63.13 6 4.00 0.07
SD (ms) 33.1 6 2.53 34.5 6 2.03 0.63 36.5 6 4.48 36.8 6 3.70 0.90
rMSSD (ms) 20.9 6 3.12 22.4 6 1.51 0.65 19.5 6 1.92 20.9 6 1.47 0.24
pNN50 (%) 5.3 6 2.6 4.1 6 0.71 0.67 3.0 6 0.97 3.3 6 0.89 0.63
MIN HR (beats/min) 59.1 6 2.27 47.5 6 1.57 , 0.001 53.1 6 1.85 45.8 6 2.08 , 0.001
Average HR 88.0 6 2.61 69.8 6 1.86 , 0.001 83.1 6 2.93 69.9 6 2.00 , 0.001
MAX HR (beats/min) 133.2 6 5.17 106.7 6 3.69 , 0.001 134.6 6 7.06 109.0 6 4.75 , 0.001
HF 5 high-frequency power (0.15–0.40 Hz); HR 5 heart rate; LF 5 low-frequency power (0.04–0.15 Hz); NN 5 mean of all coupling intervals between normal beats;
pNN50 5 proportion of adjacent RRs more than 50 ms different; rMSSD 5 root-mean square of difference of successive RRs; SD 5 mean of all 5-min standard deviation of
RRs; SDANN 5 standard deviation of 5-min mean RR intervals; SDNN 5 standard deviation about the mean; Total power 5 all frequencies (0.01–1.0 Hz).
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tality. The majority of our patients had an SDNN of about
80 ms. However, we were unable to demonstrate any
improvement in this value after treatment with either
metoprolol or carvedilol.
Study limitations. This study had a relatively small num-
ber of patients, and there is a possibility of a type II error. It
was not powered to detect any differences in mortality and
was designed to determine if there were any obvious or
major differences in clinical efficacy, especially in terms of
symptoms, quality of life and exercise capacity between the
two drugs. To this extent, we used a wide range of
well-validated techniques including the Minnesota Heart
Failure Symptom Questionnaire and the 6-min walk test.
Several studies have now demonstrated a clear independent
inverse relation between the 6-min walk test and both
mortality and morbidity (15). We did not have a placebo
group in the study. At the time of planning this study,
several larger scale studies had already confirmed the benefit
of beta-blockade in chronic heart failure compared with
placebo. Furthermore, in our previous study (7), there were
no significant changes in symptoms or exercise capacity on
LV ejection fraction over the 12-week study period in the
placebo group. There was a nonsignificant trend for im-
provement of symptoms, but LV ejection fraction fell in
direct contrast to the beta-blockade groups.
CONCLUSIONS
In this study, we have confirmed the beneficial effects of
metoprolol and carvedilol in patients with chronic heart
failure. We were unable to show any differences between
carvedilol and metoprolol on symptoms, quality of life,
exercise capacity or LV ejection fraction. Carvedilol did
lower both systolic and diastolic blood pressure significantly
more than metoprolol and normalized the mitral E wave
deceleration time. It is possible that these additional effects
on blood pressure and diastolic function, which may be
mediated by alpha receptor blockade, will be translated into
improved mortality and morbility in the longer term, but in
terms of improving symptoms, exercise capacity or LV
ejection fraction, the additional actions of carvedilol do not
appear to provide any extra benefit compared with meto-
prolol.
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